Genetics Poly Cystic Ovary Syndrome

afrouz khazamipour


Background: Polycystic ovarian syndrome is a complicated hereditary disorder which does not have specific reason and 6-10% of women at fertility age are involved. In other word we can say that this syndrome is a familial hereditary syndrome which developed with combination of environmental and genetic factors. Polycystic ovarian syndrome (PCOS) is related to cardiovascular diseases and has psychological and neurological effects on life quality as well as uterine and breast cancers. The main criteria for diagnosis of polycystic ovarian syndrome are chronic anovulation and hyperandogenism and the sub-criteria are insulin resistance, hirsutism and obesity onset at menarche age, anovulation alternatively is associated with increased testosterone level and DHEA-S. The cause of polycystic ovarian syndrome (PCO) is unknown, but it could be the result of complex genetic factors which are evident at puberty onset, also hereditary and non-hereditary factors could be the cause of polycystic ovarian syndrome (PCO) phenotype. In many women with polycystic ovarian syndrome, the insulin level is high. It seems that high levels of insulin increase androgens production. High levels of androgens can cause acne, supernumerary hair growth, weight gain, and ovulation problem. Conclusion: Early diagnosis and treatment of polycystic ovarian syndrome could help to reduce long-term complications such as diabetes type II, high blood pressure, heart disease and stroke.

Full Text:



Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29(2):181-91

Edwards RG, Beard HK. Is the success of human IVF more a matter of genetics and evolution thangrowing blastocysts? Hum Reprod. 1999 Jan; 14(1): 1-4.

Engmann L, Maconochie N, Sladkevicius P, Bekir J, Campbell S, Tan SL. The outcome of in-vitrofertilization treatment in women with sonographic evidence of polycystic ovarian morphology. HumReprod. 1999 Jan; 14(1): 167-71 .

Glueck CJ, Papanna R, Wang P, Goldenberg N,Sieve-Smith L. Incidence and treatment of metabolicsyndrome in Expert Rev. Obstet. G 86 ynecol. 5(1),(2010) Review Massicotte, Langlois & Baillargeonnewly referred women with confirmed polycysticovarian syndrome. Metabolism 52(7), 908–915(2003)

Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A.Evaluation of metabolic syndrome frequency andpremature carotid atherosclerosis in young womenwith polycystic ovary syndrome. Hum. Reprod.20(9), 2409–2413 (2005).

Gambineri A, Pelusi C, Manicardi E et al. Glucoseintolerance in a large cohort of mediterranean womenwith polycystic ovary syndrome: phenotype andassociated factors. Diabetes 53(9), 2353–2358 (2004).

Weerakiet S, Srisombut C, Bunnag P, Sangtong S,Chuangsoongnoen N, Rojanasakul A. Prevalence ofType 2 diabetes mellitus and impaired glucosetolerance in Asian women with polycystic ovarysyndrome. Int. J. Gynaecol. Obstet. 75(2), 177–184(2001).

Legro RS, Kunselman AR, Dodson WC, Dunaif A.Prevalence and predictors of risk for Type 2 diabetesmellitus and impaired glucose tolerance in polycysticovary syndrome: a prospective, controlled study in254 affected women. J. Clin. Endocrinol. Metab.84(1), 165–169 (1999).

Ehrmann DA, Barnes RB, Rosenfield RL,Cavaghan MK, Imperial J. Prevalence of impairedglucose tolerance and diabetes in women withpolycystic ovary syndrome. Diabetes Care 22(1),141–146 (1999).

Legro RS, Gnatuk CL, Kunselman AR, Dunaif A.Changes in glucose tolerance over time in womenwith polycystic ovary syndrome: a controlled study. J.Clin. Endocrinol. Metab. 90(6), 3236–3242 (2005).

Cascella T, Palomba S, De Sio I ,et al. Visceral fatis associated with cardiovascular risk in women withpolycystic ovary syndrome. Hum. Reprod. 23(1), 53-159 (2008).

Shroff R, Kerchner A, Maifeld M, Van Beek EJ,Jagasia D, Dokras A. Young obese women withpolycystic ovary syndrome have evidence of earlycoronary atherosclerosis. J. Clin. Endocrinol. 92(12), 4609–4614 (2007).

Lakhani K, Hardiman P, Seifalian AM. Intima–media thickness of elastic and muscular arteries ofyoung women with polycystic ovaries.Atherosclerosis 175(2), 353–359 (2004)

Talbott E, Zborowski J, Rager J, Boudreaux M, Edmundowicz D, Guzick D. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2004;89(11):5454-61

Orio F Jr, Palomba S, Cascella T, et al. Earlyimpairment of endothelial structure and function inyoung normal-weight women with polycystic ovarysyndrome. J. Clin. Endocrinol. Metab. 89(9), 4588–4593 (2004).

Solomon CG, Hu FB, Dunaif A et al. Menstrualcycle irregularity and risk for future cardiovasculardisease. J. Clin. Endocrinol. Metab. 87(5), 2013–2017(2002). Metab.

Tsilchorozidou T, Overton C, Conway GS, Thepathophysiology of polycystic ovary syndrome. ClinEndocrinol (Oxf). 60 (2004) 1-17.

Kazerooni T, Asadi N, Dehbashi S, Zolghadri J, Effectof folic acid in women with and without insulinresistance who have hyperhomocysteinemic polycysticovary syndrome. Int J Gynaecol Obstet. 101 (2008)156-160.

Palep-Singh M, Picton HM, Yates ZR, Barth JH, BalenAH, Plasma homocysteine concentrations and the singlenucleotide polymorphisms in the methionine synthasegene (MTR 2756A>G): Associations with the polycysticovary syndrome An observational study. Eur J ObstetGynecol Reprod Biol. 138 (2008) 180-186.

Farhud DD,Malmir M,khanahmadi M(2015).Happiness as a healthy lifestyle Iranian Academy of Medical Science. Iran J Public Health, Vol. 44, No.11, Nov 2015, pp.1442-1444

DD Farhud , M Zarif Yeganeh,nutrigenomics and nutrigenetics. Iranian J Publ Health, Vol. 39, No.4, 2010, pp.1-14.

Marx TL, Mehta AE. Polycystic ovary syndrome:pathogenesis and treatment over the short and long term.Cleveland Clinic J Med 70 (2003) 31-45.

Speroff L, Fritz M. Anovulation and the polycysticovary. Clinical Gynecology Endocrinology andInfertility. 2005; 7th Edition: 465-498.

Marc A. Fritz And Leon Speroff Clinical Gynecologic Endocrinology and Infertility-2011,Volume1

McARTHUR JW, INGERSOLL FM, WORCESTER J. The urinary excretion of interstitial-cell and follicle-stimulating hormone activity by women with diseases of the reproductive system. Journal of Clinical Endocrinology & Metabolism. 1958;18(11):1202-15

Yen S. C., Vela, P. and Rankin, J.(1970). Inappropriate secretion of follicle- stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab.30:435-42

Chang PL, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, et al. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. Journal of Clinical Endocrinology & Metabolism. 2000;85(3):995-1000.

Apter D, Vihko R. Premenarcheal endocrine changes in relation to age at menarche. Clinical endocrinology. 1985;22(6):753-60

Balen AH, Conway GS, Kaltsas G, Techatraisak K, Manning PJ, West C, et al. Andrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.

Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. Journal of Clinical Endocrinology & Metabolism. 1999;84(6):1897-9.

Atiomo WU, Condon J, Adekanmi O, Friend J, Wilkin TJ, Prentice AG. Are women with polycystic ovary syndrome resistant to activated protein C? Fertility and sterility. 2000;74(6):1229-32.

BURGHEN GA, GIVENS JR, KITABCHI AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. Journal of Clinical Endocrinology & Metabolism. 1980;50(1):113-6.

Duaif A, Graf M, Mandeli J, LaumasV, Dobrjansky A. Characterization of Groups of Hyperaiidrogenic Women with Acanthosis Nigricans, Impaired Glucose Tolerance, and/or Hyperinsulinemia. Journal of Clinical Endocrinology & Metabolism. 1987;65(3):499-507.

Escobar-Morreale HF, Roldán B, Barrio R, Alonso M, Sancho J, de la Calle H, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism. 2000;85(11):4182-7.

LANZONE A, CARUSO A, DI SIMONE N, DE CAROLIS S, Fulghesu A, MANCUSO S. Polycystic ovary disease: A risk factor for gestational diabetes? Journal of reproductive medicine. 1995;40(4):312-6.

Lanzone A, Fulghesu A, Cucinelli F, Guido M, Pavone V, Caruso A, et al. Endocrinology: Preconceptional and gestational evaluation of insulin secretion in patients with polycystic ovary syndrome. Human reproduction. 1996;11(11):2382-6.

Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clinical endocrinology. 2000;52(1):81-6.

Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocrine reviews. 1995;16(2):117-42.

Robert Y, Dubrulle F, Gaillandre L, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, et al. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computerized quantification. Fertility and sterility. 1995;64(2):307.

Farah L, Lazenby A, Boots L, Azziz R. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Journal of reproductive medicine. 1999;44(10):870-4.

Ovesen P, Moller J, Ingerslev HJ, Jørgensen J, Mengel A, Schmitz O, et al. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1993;77(6):1636-40

Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Human reproduction. 2000;15(6):1266-74.

Bringer J, Lefebvre P, Boulet F, Grigorescu F, Renard E, Hedon B, et al. Body Composition and Regional Fat Distribution in Polycystic Ovarian Syndrome Relationship to Hormonal and Metabolic Profiles. Annals of the New York Academy of Sciences. 1993;687(1):115-23.

Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1995;80(9):2586-93.

Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle- stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. Journal of Clinical Endocrinology & Metabolism. 1996;81(1):302-9.

Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. Journal of Clinical Endocrinology & Metabolism. 1998;83(11):3984-91.

Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from womenpolycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. Journal of Clinical Endocrinology & Metabolism. 1998;83(6):2001-5.

Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. Journal of Clinical Investigation. 1989;83(1):23

Wehr, E., Pilz, S., Schweighofer, N. (2009) Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. European Journal of Endocrinology, 0, EJE-9– EJE0432.

Ngo, D.T.M., Chan, W.P., Rajendran, S. (2011) Determinants of insulin responsiveness in young women: Impact ofpolycystic ovarian syndrome, nitric oxide, and vitamin D. NitricOxide, 25, 326–330.

Rebecca L. Thomson, Simon Spedding and Jonathan D. BuckleyVitamin D in the aetiology and management of polycystic ovarysyndromeClinical Endocrinology (2012) 77, 343–350

Mahmoudi, T., Gourabi, H., Ashrafi, M. (2010) Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertility and Sterility, 93, 1208–1214.

Panidis, D., Balaris, C., Farmakiotis, D. (2005) Serum parathyroidhormone concentrations are increased in women withpolycystic ovary syndrome. Clinical Chemistry, 51, 1691–1697.

Zborowski JV, Talbtt EO, Cauley JA. Polycystic ovarysyndrome, androgen excess, and the impact on bone.Obstet Gynecol Clininical North Am. 2001; 28(1):135-51.

Jorde R, Sundsfyord J, Haug E, Bonaa KH. Relationbetween low calcium intake, parathyroid hormone, andblood pressure. Hypertention 2000;35:1154-9.

Bostick RM, Kushi LH, Wu Y, Meyer KA, SellersTA, Folsom AR. Relation of calcium, vitamin D, anddairy food intake to ischemic heart disease mortalityamong postmenopausal women. Am J Epidemiol 1999;149:151-61

Thys- Yacobs S, Donovan D, Papadopoulos A, SarrelP,Bilezikian J.P. Vitamin D and Calcium dysregulationin the polycystic ovarian syndrome. Steroids 1999; 64:430-5.

Homa ST, Carroll J, Swann K. The role of calcium inmammalian oocyte maturation and egg activation.Hum Reprod 1993;8:1274-81.

Kaufman M, Homa ST. Defining a role for calcium inthe resumption and progression of meiosis in the pigoocyte. J Exp Zool. 1993;265:69-76.

Rebecca L.Thomson,simon spending and jonathan D.Buckley.vitamin D in the aetiology and management of polycystic ovary syndrome.clinical Endrocrinology.2012:77.343-350.

Cooper HE, Spellacy W, Prem K, Cohen W. Hereditary factors in the Stein-Leventhal syndrome. American journal of obstetrics and gynecology. 1968;100(3):371.

Chen Z, Shi Y, Zhao Y, Li Y, Tang R, Zhao L, et al. Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Zhonghua fu chan ke za zhi. 2004;39(9):582

Legro RS, Driscoll D, Strauss JF III, Fox J, Dunaif A. Evidence for a genetic basisfor hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad SciUSA 1998;95:14956–14960.

Franks, S. Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. J. Clin. Endocrinol. Metab. 93, 3396–3402(2008).

Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. The genetic basis of polycystic ovary syndrome. Human reproduction. 1997;12(12):2641- 8.

March RE. Gene mapping by linkage and association analysis. Molecular biotechnology. 1999;13(2):113-22.

Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine. 2005;352(12):1223-36.

Conway GS, Avey C, Rumsby G. Genetics: The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Human reproduction. 1994;9(9):1681-3.

Ehrmann DA. 7 Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus. Baillière's clinical obstetrics and gynaecology. 1997;11(2):335-47.

Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nature genetics. 2000;26(2):163-75.

Hyejin Lee, Jee-Young Oh, Yeon-Ah Sung, Hyewon Chung,Hyung-Lae Kim, Gwang SubKim, Yoon Shin Cho, et al.Genome-wide association study identified newsusceptibility locifor polycystic ovary syndrome. Human Reproduction, Vol.30, No.3 pp. 723–731, 2015

Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycysticovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab2006;91:2100–2104.

Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol CellEndocrinol 2013;373:29–38.Kumar U, Sasi R, Suresh S, Patel

Hwang JY, Lee EJ, Jin Go M, Sung YA, Lee HJ, Heon Kwak S, et al. Genome-wide association studyidentifies GYS2 as a novel genetic factor for polycystic ovary syndromethrough obesity-related condition. J Hum Genet 2012;57:660–664.

Kim JJ, Choi YM, Cho YM, Hong MA, Chae SJ, Hwang KR,et al. Polycystic ovary syndrome is not associated withpolymorphisms of the TCF7L2, CDKAL1, HHEX, KCNJ11, FTO andSLC30A8 genes. Clin Endocrinol (Oxf) 2012;77:439–445.

Yun JH, Gu BH, Kang YB, Choi BC, Song S, Baek KH. Association betweenINS-VNTR polymorphism and polycystic ovary syndrome in a Koreanpopulation. Gynecol Endocrinol 2012;28:525–528.

Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Li Z, et al. Genome-wide association study identifies susceptibility loci for polycysticovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet2011;43:55–59.

Shi Y, Zhao H, Cao Y, Yang D, Li Z, Zhang B, et al. Genome-wide association study identifies eight newrisk loci for polycysticovary syndrome. Nat Genet 2012;44:1020–1025.

Luque-Ramírez M, San Millán JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clinica chimica acta. 2006;366(1):14-26

Valdés P, Cerda A, Barrenechea C, Kehr M, Soto C, Salazar LA. No association between common Gly972Arg variant of the insulin receptor substrate-1 and polycystic ovary syndrome in Southern Chilean women. Clinica chimica acta. 2008;390(1):63-6.

Azziz R, Kashar-Miller M. Family history as a risk factor for the polycystic ovary syndrome. Journal of pediatric endocrinology & metabolism: JPEM. 2000;13:1303.

Zhang L, Guo L, Peng Y, Chen B. Expression of T-STAR gene is associatedwith regulation of telomerase activity in human colon cancer cell lineHCT-116. World J Gastroenterol 2006;12:4056–4060.

Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS,Ghiringhelli PD, Alonso DF. Telomere structure and telomerase inhealth and disease (review). Int J Oncol 2012;41:1561–1569.

Nordfjall K, Larefalk A, Lindgren P, Holmberg D, Roos G. Telomere lengthand heredity: indications of paternal inheritance. Proc Natl Acad Sci USA2005;102:16374–16378.

Roger L, Jones RE, Heppel NH, Williams GT, Sampson JR, Baird DM.Extensive telomere erosion in the initiation of colorectal adenomas andits association with chromosomal instability. J Natl Cancer Inst 2013;105:1202–1211.

Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J,Packard CJ, Samani NJ. Telomere length, risk of coronary heart disease,and statin treatment in the West of Scotland Primary Prevention Study:a nested case-control study. Lancet 2007;369:107–114.

Cohen S, Janicki-Deverts D, Turner RB, Casselbrant ML, Li-Korotky HS,Epel ES, Doyle WJ. Association between telomere length andexperimentally induced upper respiratory viral infection in healthyadults. JAMA 2013;309:699–705.

Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M, et al. Telomere dysfunction induces metabolic andmitochondrial compromise. Nature 2011;470:359–365.

Guo N, Parry EM, Li LS, Kembou F, Lauder N, Hussain MA, et al. Short telomeres compromise beta-cell signaling andsurvival. PLoS One 2011;6:e17858.

LeeHW, Blasco MA, Gottlieb GJ, Horner JW II, GreiderCW, DePinho RA.Essential role of mouse telomerase in highly proliferative organs. Nature1998;392:569–574.

Meredith A. Brower, Michelle R. Jones, Jerome I. Rotter, Ronald M. Krauss,Richard S. Legro, Ricardo Azziz, and Mark O. Goodarzi Further Investigation in Europeans of SusceptibilityVariants for Polycystic Ovary Syndrome Discovered inGenome-Wide Association Studies of ChineseIndividuals J Clin Endocrinol Metab, January 2015, 100(1):E182–E186.

Goodarzi MO, Jones MR, Li X, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet. 2012;49:90–95.

Welt CK, Styrkarsdottir U, Ehrmann DA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. JClin Endocrinol Metab. 2012;97:E1342–E1347.

McAllister JM, Modi B, Miller BA, et al. Overexpression of aDENND1A isoform produces a polycystic ovary syndrome thecaphenotype. Proc Natl Acad Sci USA. 2014;111:E1519–E1527.

Wang P, Zhao H, Li T, et al. Hypomethylation of the LH/choriogonadotropin receptor promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome. Endocrinology.2014;155:1445–1452.

Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, et al. Thirty- seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is withfollistatin. Proceedings of the National Academy of Sciences. 1999;96(15):8573-8.

Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic ovary syndrome Boston: Blackwell Scientific. 1992;377.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2745-9.

Govind A, Obhrai M, Clayton R. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families

Gonzalez A, Abril E, Roca A, Aragón MJ, Figueroa MJ, Velarde P, et al. CAPN10 alleles are associated with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2002;87(8):3971-6

Dr Dariush Farhud, Noushin Niknat, Dr. Mahmood Mahmoodi, Attitude of a group of doctors, nurses and midwives in Tehran on the principles of ethics in medical genetics, Iranian Journal of Health, Vol. 28, No. 1-4,1378.



  • There are currently no refbacks.

Copyright (c) 2018 Asian Pacific Journal of Cancer Biology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.





Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention